Meeting
2014 ASCO Annual Meeting
Combined chemoimmunotherapy of castrate-resistant prostate cancer with dendritic-cell based vaccine DCVAC/Pca.
Authors
Michal Podrazil
2nd Medical School Charles University, Prague, Czech Republic
Michal Podrazil , Daniela Rozkova , Jitka Fucikova , Stanislav Katina , Radek Spisek , Jirina Bartunkova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Vaccines
Clinical Trial Registration Number
2009-017259-24
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3095)
DOI
10.1200/jco.2014.32.15_suppl.3095
Abstract #
3095
Poster Bd #
162
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Development of a predictive model of PSA response to a switch from prednisone to dexamethasone in metastatic castrate-resistant prostate cancer patients biochemically progressing on abiraterone.
First Author: Reeta Barua
Poster
2019 ASCO Annual Meeting
Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
First Author: Christophe Massard
Poster
2019 Genitourinary Cancers Symposium
Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
First Author: Christophe Massard
Poster
2019 Genitourinary Cancers Symposium
A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Munjid Al Harthy